Jubilant Pharmova has released its audited financial results for the quarter and financial year ended March 31, 2026. The company reported a strong fiscal performance, with consolidated revenue reaching ₹83,456 million for the year. Following these results, the Board of Directors has recommended a final dividend of 500%, amounting to ₹5 per equity share, subject to shareholder approval at the upcoming Annual General Meeting.
Fiscal Year Performance
Jubilant Pharmova concluded the financial year ending March 31, 2026, with solid financial growth. Consolidated revenue for the year stood at ₹83,456 million, marking a significant increase compared to the previous year’s ₹72,913 million. The company reported a profit for the year of ₹3,975 million, underscoring its operational resilience throughout the fiscal period.
Dividend Declaration
Recognizing the company’s financial health, the Board of Directors has recommended a final dividend of 500% for the financial year ended March 31, 2026. This translates to ₹5 per equity share of face value Re. 1 each. The dividend payment is slated for approval by shareholders at the next Annual General Meeting, with the record date for the payout fixed for Friday, July 24, 2026.
Operational Insights
The company’s results, which were approved by the Board on May 22, 2026, reflect continued growth across its diversified segments, including Radiopharma, Allergy Immunotherapy, and Contract Research and Manufacturing services. The consolidated results received an unmodified audit opinion, reinforcing transparency and sound financial reporting practices. Additionally, the company is actively monitoring the impact of the newly notified Labour Codes and is evaluating their consequential effects on future operations.
Source: BSE
